Table 1 Patient characteristics and treatment outcome across VEN14, VEN21, and VEN28.

From: Comparable outcomes with 14-, 21-, or standard 28-day venetoclax in the first cycle of azacitidine–venetoclax in untreated acute myeloid leukemia: real-world experience from the Hokkaido Leukemia Net

 

VEN 14 (n = 31)

VEN 21 (n = 51)

VEN 28 (n = 18)

p-value

Median age, year (range)

79 (63–87)

71 (61–88)

76 (63–91)

0.708

Male n (%)

19 (61.3%)

29 (56.9%)

8 (44.4%)

0.511

Median follow-up

456 days (13–1141)

384 days (19–1291)

226 days (37–1155)

Secondary AML

7 (22.6%)

13 (25.5%)

3 (16.7%)

0.745

Prior MDS

4 (12.9%)

12 (23.5%)

0 (0.0%)

0.079

Therapy-related AML

3 (9.7%)

1 (2.0%)

3 (1.7%)

0.054

Cytogenetics

   

0.100

Normal

15 (19.4%)

19 (37.3%)

6 (33.3%)

 

Complex

2 (6.5%)

13 (25.5%)

7 (38.9%)

 

Others

14 (45.2%)

19 (37.3%)

5 (27.8%)

 

Mutaions

 FLT3-ITD

5 (16.1%)

2 (3.9%)

2 (11.1%)

0.150

 NPM-1

3 (9.7%)

4 (7.8%)

5 (27.8%)

0.086

 IDH1/IDH2

9 (29.0%)

12 (23.5%)

5 (27.8%)

0.844

 N/KRAS

0 (0.0%)

2 (3.9%)

0 (0.0%)

0.681

 TP53

9 (29.0%)

14 (27.5%)

7 (38.9%)

0.654

HLN risk stratification for AZA-VEN

   

0.304

 Sensitive (n = 32)

12 (38.7%)

14 (27.5%)

6 (33.3%)

 

 Intermediate (n = 39)

13 (41.9%)

22 (43.1%)

4 (22.2%)

 

 Unfavorable (n = 29)

6 (19.4%)

15 (29.4%)

8 (44.4%)

 

Azole prophylaxis in 1st cycle

7 (22.6%)

19 (37.3%)

3 (16.7%)

0.162

G-CSF in 1st cycle

12 (38.7%)

23 (45.1%)

5 (27.8%)

0.429

Median VEN dose (range)

200 mg (50–400)

400 mg (50–400)

400 mg (50–400)

0.021

CRc rate(%)

 All patients

21 (67.7%)

26 (51.0%)

7 (38.9%)

0.123

 VEN-sensitive (n = 32)

10 (83.3%)

10 (71.4%)

5 (83.3%)

0.857

 VEN-intermediate (n = 39)

8 (61.5%)

10 (45.6%)

1 (25.0%)

0.369

 VEN-unfavorable (n = 29)

3 (50.0%)

6 (40.0%)

1 (12.5%)

0.336

Grade 4 neutropenia (%)

21 (67.7%)

40 (78.4%)

9 (50.0%)

0.073

Febrile neutropenia (%)

17 (54.8%)

24 (47.1%)

7 (38.9%)

0.550

Documented infection (%)

8 (25.8%)

6 (11.7%)

3 (16.7%)

0.260

Duration of grade 4 neutropenia (days)

29 days (21–57)

32 days (24–52)

33 days (20–63)

0.731

Duration of febrile neutropenia (days)

5 days (1–15)

4 days (1–42)

7 days (2–25)

0.890

Median OS (days)

481 days

438 days

240 days

0.210

Back to article page